Denali Therapeutics (DNLI)
NASDAQ:DNLI

Denali Therapeutics (DNLI) Income Statement

401 Followers

Denali Therapeutics Income Statement

Last quarter (Q1 2023), Denali Therapeutics's total revenue was $35.14M, a decrease of -16.61% from the same quarter last year. In Q1, Denali Therapeutics's net income was $202.13M. See Denali Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ 91.18M$ 105.06M$ 48.66M$ 335.66M$ 26.68M$ 129.16M
Cost of Revenue
------
Gross Profit
$ 35.14M$ 105.06M----
Operating Expense
$ 68.98M$ -449.21M$ 344.41M$ 272.94M$ 239.86M$ 175.53M
Operating Income
$ 22.20M$ -344.14M$ -295.75M$ 62.72M$ -213.18M$ -46.37M
Net Non Operating Interest Income Expense
$ 17.87M$ 14.77M$ 4.59M$ 9.24M$ 15.22M$ 10.13M
Other Income Expense
-$ -3.40M----
Pretax Income
$ 40.06M$ -325.97M$ -291.16M$ 71.96M$ -197.97M$ -36.24M
Tax Provision
$ 27.00K$ 21.00K$ -575.00K$ 823.00K$ -351.00K$ 0.00
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ 40.04M$ -325.99M$ -290.58M$ 71.14M$ -197.61M$ -36.24M
Basic EPS
$ -2.12$ -2.60$ -2.39$ 0.65$ -2.07$ -0.39
Diluted EPS
$ -2.12$ -2.60$ -2.39$ 0.63$ -2.07$ -0.39
Basic Average Shares
$ 383.01M$ 125.53M$ 121.52M$ 108.97M$ 95.61M$ 92.62M
Diluted Average Shares
$ 383.01M$ 125.53M$ 121.52M$ 112.70M$ 95.61M$ 92.62M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 68.98M$ -449.21M$ 344.41M$ 272.94M$ 239.86M$ 175.53M
Net Income From Continuing And Discontinued Operation
$ -271.87M$ -325.99M$ -290.58M$ 71.14M$ -197.61M$ -36.24M
Normalized Income
$ -162.09M-$ -290.58M$ 71.14M$ -197.61M$ -36.24M
Interest Expense
------
EBIT
$ 22.20M$ -340.74M$ -295.75M$ 62.72M$ -213.18M$ -46.37M
EBITDA
$ 36.45M$ -330.34M$ -287.16M$ 71.25M$ -205.19M$ -38.96M
Currency in USD

Denali Therapeutics Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis